Investors Are Waking Up To Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) After Losing -97.03% Over The Past 12 Months

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) currently has a daily average trading volume of 75.58M but it saw 713046477 shares traded in last market. With a market cap of 106.53M USD, the company’s current market price of $0.57 came rising about 56.25 while comparing to the previous closing price of $0.36. In past 52 weeks, the stock remained buoying in the range of price level as high as $22.14 and as low as $0.12. In the recent trading on the day, stock has struck highest price mark of $0.32 while lowest mark touched by it was $0.72.

Taking a look at 20-day trading activity of Tonix Pharmaceuticals Holding Corp (TNXP) gives us an average price of $0.2455, while its current price level is -97.43% below from 52-week high level whereas it is 383.05% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $0.1909 while that of 200 days or SMA-200 reads an average of $2.4636. A closer look into the stock’s movement over the week reveals that its volatility is standing at 113.61% during that period while stretching the period over a month that decreases to 38.47%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 73.53 which implies that the stock is in overbought territory.

ROTH Capital upgraded its recommendation for the stock as a “Buy” from “Neutral” on April 18, 2019 while assigning a price target of $4. ROTH Capital issued its recommendations for the stock as it upgraded the price target for the stock is $6.

Over the week, TNXP’s stock price is moving 149.02% up while it is 250.34% when we observe its performance for the past one month. Year-to-date it is -95.58% down and over the past year, the stock is showing a downside performance of -97.03%.

The company is expected to be releasing its next quarterly report in January, for which analysts forecasted an EPS of -7.68 while estimate for next year EPS is -35.52. In next quarter, company is expected to be making quarterly sales of $4.1M as analysts are expecting the sales for current fiscal year at $12.54M and seeing the company making $15.62M in sales next year. Moreover, analysts are in estimates of $3.4M for current-quarter revenue.

Currently, Tonix Pharmaceuticals Holding Corp’s total number of outstanding shares is 186.89M. Company’s return on investment (ROI) stands at -169.47% and return on equity (ROE) at -138.69%. Stock’s beta reads 1.97. Stock has a price to book (P/B) ratio of 1.20 while price to sale or P/S ratio amounts to 9.44. Its return on asset (ROA) is -115.46% on average.